Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience

Fiorina Giona, Maria C. Putti, Concetta Micalizzi, Giuseppe Menna, Maria L. Moleti, Nicola Santoro, Grazia Iaria, Saverio Ladogana, Roberta Burnelli, Caterina Consarino, Stefania Varotto, Francesca Tucci, Chiara Messina, Mauro Nanni, Daniela Diverio, Andrea Biondi, Andrea Pession, Franco Locatelli, Alfonso Piciocchi, Enrico GottardiGiuseppe Saglio, Robin Foà

Research output: Contribution to journalArticlepeer-review

Abstract

Imatinib mesylate (IM) is used for the management of childhood chronic myeloid leukaemia (CML). The most effective dosage of IM and its long-term efficacy in children are not well defined. The purpose of this multicentre study is to report on the long-term results of high-dose IM (340 mg/m2 /d) in CML patients in chronic phase (CP-CML) aged

Original languageEnglish
Pages (from-to)398-407
Number of pages10
JournalBritish Journal of Haematology
Volume170
Issue number3
DOIs
Publication statusPublished - Aug 1 2015

Keywords

  • BCR-ABL1
  • childhood
  • chronic myeloid leukaemia
  • imatinib
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience'. Together they form a unique fingerprint.

Cite this